NCT03769116View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

December 8, 2020

Study Completion Date

August 16, 2023

Conditions
Muscular Dystrophy, Duchenne
Interventions
GENETIC

delandistrogene moxeparvovec

Single IV infusion of delandistrogene moxeparvovec

GENETIC

placebo

Single IV infusion of matching placebo

Trial Locations (2)

43205

Nationwide Children's Hospital, Columbus

90095

David Geffen School of Medicine at UCLA, Los Angeles

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT03769116 - A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter